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r e v i e w
Progress at the beginning of the 21st century transformed the perception of complement from that of a blood-based antimicrobial system to that of a global regulator of immunity and tissue homeostasis. More recent years have witnessed remarkable advances in structure-function insights and understanding of the mechanisms and locations of complement activation, which have added new layers of complexity to the biology of complement. This complexity is readily reflected by the multifaceted and contextual involvement of complement-driven networks in a wide range of inflammatory and neurodegenerative disorders and cancer. This Review provides an updated view of new and previously unanticipated functions of complement and how these affect immunity and disease pathogenesis.
New discoveries about the functional versatility of complement have raised the question of how a small set of proteins can provide distinct, dynamic and context-tailored responses. Advances in biophysical methods, especially cryogenic electron microscopy 4 , have led to an increasingly refined picture not only of individual complement components but also of intricate complexes, such as the C3 convertases or the MAC 5, 6 . Thus, their dynamic conversions and interactions are beginning to be elucidated, the molecular and functional consequences of genetic alterations in complement proteins can be mapped and predicted and therapeutic strategies can be designed and rationalized.
Recent studies have shown that complement is not an exclusively liver-derived intravascular and extracellular system. Complement components can be secreted locally by tissue-resident and infiltrating cells, while emerging evidence suggests the existence of an intracellular complement system with novel homeostatic and immunological functions 2 . New insights into the mechanisms and locations of complement activation have revealed an additional layer of complexity in the biology of complement and its effect on health and disease 7, 8 . When it is dysregulated or overactivated due to host genetic or microbial virulence factors, complement can turn from a homeostatic effector to a pathological effector that drives various inflammatory disorders and cancers, which reflects the multifaceted nature of complement interactions 3, 9 . This Review critically summarizes an updated view of hitherto unanticipated functions of complement and its pervasive role in immunity and disease.
Regulation of the host response by complement Complement has been historically linked to the regulation of humoral adaptive immunity by virtue of its ability to lower the activation threshold of B cells that engage antigens opsonized with C3b-degradation products (iC3b and C3dg) via the complement receptor CR2 on the B cell co-receptor complex (CR2-CD19-CD81) 1, 10 . Subsequently, complement was shown to also regulate cell-mediated adaptive immunity 11 . The stimulatory effects of complement on the activation of T cells could be attributed in part to regulation of the maturation and function of antigen-presenting cells (APCs) by C3a or C5a. However, the finding that C3a and C5a can be produced locally at the APC-T cell interface, where reciprocal cognate interactions seem to upregulate the expression of anaphylatoxin receptors in both partners, suggests that complement might have direct effects on the functional co-stimulation and differentiation of naive CD4 + T cells 12 .
The activation of complement anaphylatoxins might not necessarily occur in the extracellular milieu, and studies have substantiated the existence of intracellular stores of complement components and receptors (e.g., anaphylatoxin receptors and their ligands; and C3b, factor B (FB) and factor H (FH)), which perform novel homeostatic and surveillance functions within human T cells 7, 13, 14 . A cell-intrinsic and functionally active complement system was anticipated more than 30 years ago by pioneering studies showing that human lymphocytes synthesize various complement components, regulators and receptors 15, 16 . An intracellular complement system has been observed also in fibroblasts, endothelial cells and epithelial cells, although the mechanisms underlying its activation and regulation and its functional outcomes remain largely unexplored 17 . A rapid and saturable recycling pathway has been identified for C3 in lymphocytes that allows exchange between intracellular stores and extracellular sources 18 .
C3 can be activated tonically in human CD4 + T cells through cleavage by cathepsin L into C3a and C3b. The tonically generated C3a activates its cognate receptor C3aR on lysosomes, and this intracellular C3a-C3aR signaling pathway mediates the homeostatic survival of T cells by maintaining low-level activity of the metabolic-checkpoint kinase mTOR 13 (Fig. 1) . Resting CD4 + T cells do not display surface C3aR or cathepsin L. However, activation of the T cell antigen receptor (TCR) and co-stimulation via the co-receptor CD28 induces translocation ('shuttling') of this intracellular C3-activation system to the cell surface, where C3aR and the complement regulator CD46 can become activated by C3a and C3b, respectively (Fig. 1) . These C3aR and CD46 signaling events upregulate the expression of growth-factor receptors, cell proliferation and the secretion of not only cytokines predominantly characteristic of the T H 1 subset of helper T cells (IFN-γ) but also T H 17-type cytokines (TNF and IL-17) without substantially affecting T H 2-type cytokines (IL-4 and IL-5) 13, 19 . Therefore, the Figure 1 Complement-mediated intracellular and autocrine regulation of the activation of CD4 + T cells. Under steady-state conditions, C3(H 2 O) is recycling between the extracellular space and the intracellular space. The intracellular stores of C3(H 2 O) constitute a source of intracellular C3a. In resting CD4 + T cells, tonic intracellular generation of C3a via cleavage by cathepsin L (CTSL) activates its receptor C3aR on lysosomes, which leads to low-level activation of mTOR for the homeostatic survival of T cells. Activation of the TCR with CD28 co-stimulation (not shown) causes translocation of this intracellular C3-activation system to the cell surface, where C3aR and CD46 are triggered by C3a and C3b, respectively. The ensuing C3aR-and CD46-mediated signaling events stimulate sustained activation of mTORC1 and reprogram glycolysis and oxidative phosphorylation (OXPHOS) in ways that support T H 1 (IFN-γ) responses. In activated CD4 + T cells, costimulation by CD46 triggers intracellular cleavage of C5 into C5a, which induces C5aR1-dependent production of reactive oxygen species; that, in turn, activates NLRP3 inflammasome-driven release IL-1β that sustains the induction of T H 1 cells. Signaling via IL-2R together with autocrine activation of CD46 induces IL-10 production, which initiates transition to a T H 1 cell population-contraction phase. That self-regulating activity is reinforced by cell-surface C5aR2 signaling induced by increased levels of secreted C5a (or C5a-desArg) resulting from the population expansion of T H 1 cells; C5aR2 downregulates C5aR1-driven activation of the NLRP3 inflammasome. r e v i e w location of complement-receptor activation (intracellular or at the cell surface) dictates the functional outcome (homeostatic survival or effector function).
The regulation of effector responses by complement proceeds through the metabolic reprogramming of CD4 + T cells. In activated human CD4 + T cells, autocrine stimulation of CD46 by C3b causes sustained activation of the mTOR complex mTORC1 and regulates glycolysis and oxidative phosphorylation in ways that promote the induction of T H 1 cells 20 (Fig. 1) . Whereas activated T cells from patients with severely reduced expression of CD46 secrete much less IFN-γ than do T cells from age-and sex-matched healthy donors, only T cells from patients with complete lack of CD46 expression fail to produce IL-17, suggestive of differences in the metabolic threshold involved in the induction of T H 1-type responses versus that of T H 17-type responses 20 . Overall, combined signaling by CD46 and C3aR is strictly required for induction of IFN-γ-expressing T H 1 cells, and normal T H 1 responses are not elicited in CD46-deficient people 13, 14, 17 . However, when the autocrine activation of CD46 occurs in combination with signaling via the cytokine receptor IL-2R in T H 1 cells (as when there is a high concentration of local IL-2 produced during the population expansion of T H 1 cells), the resulting crosstalk induces IL-10 production and promotes the transition to a self-regulating population-contraction phase for T H 1 cells 21 (Fig. 1) .
Human CD4 + T cells also contain intracellular stores of C5, although its origin (derived from serum and/or synthesized intracellularly) is uncertain. Activation of the TCR and costimulation of CD46 trigger expression of the gene encoding the cytoplasmic receptor and inflammasome component NLRP3 and intracellular activation of C5 via an unknown protease. The C5a generated induces intracellular activation of C5aR1 (within an unspecified compartment), which is required for the formation of reactive oxygen species and activation of the NLRP3 inflammasome, thereby leading to secretion of IL-1β 14 ( Fig. 1) . This C5aR1-NLRP3 crosstalk 'preferentially' induces IFN-γ production and T H 1 differentiation (but not T H 2 or T H 17 differentiation). The finding that autocrine IL-1β promotes the induction of T H 1 cells is surprising, given that APC-derived IL-1β contributes to the differentiation of T H 17 cells 22 . The C5aR1-induced activity of the NLRP3 inflammasome is downregulated by cell-surface C5aR2, which is activated in an autocrine manner by secreted C5a 14 . It is currently unknown whether the underlying mechanism involves interference with the activation of C5aR1 or a novel C5aR2-inhibitory pathway for assembly of the NLRP3 inflammasome. The activation of C5aR2 by secreted C5a (or its derivative C5a des-Arg), whose levels accumulate during the population expansion of T H 1 cells, acts together with CD46 and IL-2R in the transition to a T H 1 cell population-contraction phase (Fig. 1) .
Additional complement-mediated mechanisms for inflammasome regulation have been identified in different cell types. The ability of C5a-C5aR1 signaling to induce reactive oxygen species in mouse macrophages has been associated with potentiating activation of the NLRP3 inflammasome and release of IL-1β 23 . In human monocytes, C3a-induced activation of cell-surface C3aR triggers the release of ATP into the extracellular space and thereby regulates activation of the cation channel P2X7 and acts in synergy with signaling via Tolllike receptors (TLRs) to activate the NLRP3 inflammasome. This results in release of IL-1β from monocytes that in turn promotes the production of IL-17 by human CD4 + T cells 24 . In human epithelial cells, the formation of sublytic MACs induces fluxes in intracellular Ca 2+ that lead to activation of the NLRP3 inflammasome and release of IL-1β 25 . Similarly, deposition of sublytic C5b-9, but not deposition of C3a or C5a, activates the NLRP3 inflammasome in and the release of IL-1β by mouse dendritic cells 26 . The MAC therefore seems to mimic the well-established effect of bacterial pore-forming toxins on activation of the NLRP3 inflammasome 27 . In contrast, C1q, which binds to apoptotic cells and promotes their efferocytosis, suppresses activation of the NLRP3 inflammasome during the engulfment of apoptotic cells by human macrophages and thereby inhibits the release of IL-1β by the macrophages 28 .
The studies noted above have collectively established complement as an important regulator of inflammasome activation in various cell types, including lymphocytes, in which optimally activated T H 1 immunity requires the participation and cooperation of both C3-dependent pathways and C5-dependent pathways operating both intracellularly and extracellularly (Fig. 1) .
Complement in homeostatic immunity and microbial evasion
Microbial dysbiosis (quantitative, compositional and functional alterations to the microbiome) is associated with the pathogenesis of polygenic and multifactorial conditions, including inflammatory, autoimmune and metabolic diseases and cancer 29 . Mounting evidence suggests that complement can promote either homeostasis or dysbiosis in a contextual manner [30] [31] [32] [33] . Apart from the well-characterized C3a-and C5a-induced cell-modulation pathways, it has been shown that the C4a-activation fragment acts as an agonist for the proteaseactivated receptors PAR1 and PAR4 (ref. 34 ). This novel function not only might connect complement to hemostasis and thrombosis 35 but also suggests that what used to be thought of as the 'third anaphylatoxin' might actually endow complement with homeostatic activity, given that PAR1 can mediate anti-inflammatory effects in endothelial cells 36 .
In the skin, complement has been shown to modulate both the composition of the commensal microbiota and its diversity, presumably in part through regulation of the expression of antimicrobial peptides and inflammatory mediators 33 . Conversely, the commensal microbiota influences the basal cutaneous expression of complementencoding genes, a finding that has revealed a reciprocal relationship that maintains homeostatic host-microbiome interactions in the skin 33 . Perturbations of this homeostatic relationship promote skin inflammation. C3, which is hyperexpressed in human psoriatic epidermis, is also aberrantly upregulated in a mouse psoriasis model by calprotectin (the S100A8-S100A9 complex) and drives the disease phenotype 37 . Complement also influences cutaneous wound healing: C3 −/− and C5ar1 −/− mice exhibit an accelerated healing phenotype, which suggests that the recruitment of inflammatory cells to the wound and their activation there might delay the healing process 38 .
Pathobionts (normally under-represented microorganisms that become abundant and pathogenic when homeostasis is disrupted) exploit inflammation to thrive and outcompete commensal symbionts 39, 40 . A pathobiotic community, however, is faced with a survival conundrum: whereas pathobionts need to evade clearance by the immune system to persist, this cannot be achieved by suppression of the host response. This is because dysbiotic communities nutritionally rely on inflammatory tissue-breakdown molecules or other inflammatory byproducts that selectively favor their metabolic activity 39, 40 . In periodontitis, an oral dysbiotic inflammatory disease, complement is at the core of sophisticated tactics to subvert the immune system, whereby bacteria uncouple clearance via the immune system from the inflammatory response 41 . Porphyromonas gingivalis enzymatically cleaves C5 to generate high local concentrations of C5a for the activation of C5aR1 in neutrophils, which detect this bacterium through TLR2. This enables P. gingivalis to instigate C5aR1-TLR2 crosstalk that induces ubiquitination and proteasomal degradation of the r e v i e w TLR2 signaling adaptor MYD88, which is required for clearance of the bacteria via the immune system 41 . Additionally, the C5aR1-TLR2 crosstalk triggers an alternative pathway wherein the TLR2 MYD88-adaptor-like protein MAL mediates signaling via the kinase PI3K, which inhibits actin polymerization and phagocytosis dependent on the small GTPase RhoA while inducing a robust inflammatory response. These mechanisms promote the survival of P. gingivalis and bystander species in a nutritionally favorable inflammatory environment that is conducive for dysbiosis and disease development 41, 42 .
In other settings, complement can suppress pathobionts. In a mouse model of Clostridium difficile-induced intestinal damage and systemic spreading of pathobionts, host resistance is mediated by IL-22, which in turn is dependent on complement 32 . Mechanistically, IL-22 is required for effective induction of C3 expression in the liver and intestine, which is required for efficient opsonisation by C3b and phagocytosis of bacteria by neutrophils 32 . That study 32 highlights a previously unknown functional connection between complement and IL-22 for host protection against systemic dissemination of pathobionts after infection-induced damage to the intestinal barrier.
Another study has revealed a previously unknown C3-dependent anti-microbial mechanism that interferes with the replication of intracellular pathogens in the cytosol of non-immune cells after the pathogens escape from phagosomes 43 (Fig. 2) . Nonenveloped viruses and bacteria (e.g., adenovirus and Salmonella enterica serovar Typhimurium) that have been opsonized extracellularly with C3-cleavage fragments can be sensed in the cytosol in a C3-dependent manner and trigger mitochondrial anti-viral signaling. That signaling in turn induces the expression of pro-inflammatory cytokines through the activation of various transcription factors (NF-κB, AP-1, IRF3 and IRF5). C3-coated viruses can be additionally restricted through proteasome-mediated viral degradation 43 . The identity of the opsonizing C3-split products and the uptake receptor(s) involved in these mechanisms have not been specified. Since different cell types contain intracellular C3 that can be cleaved into C3a and C3b 13, 18 , the cell-autonomous immunological mechanisms discussed above could potentially be triggered even by intracellular pathogens that have escaped extracellular opsonization by C3b.
The transmembrane protein VSIG4 ('V-set immunoglobulindomain-containing 4'; also known as 'CRIg') is a macrophage receptor for C3b and iC3b and can promote phagocytic killing of C3-opsonized pathogens 44 . Moreover, VSIG4 has been shown to function as a pattern-recognition receptor for lipoteichoic acid that thereby enables Kuppfer cells to capture and eliminate circulating Gram-positive bacteria in the liver 45 . Another study has shown that VSIG4, moreover, can induce the formation of autophagosomes for the elimination of C3-opsonized Listeria monocytogenes that have escaped from phagosomes 46 . This intracellular anti-evasion mechanism might not involve intracellular complement, since the VSIG4 signal by itself (activated extracellularly by C3-opsonized bacteria or by agonistic antibody) is sufficient to induce autophagosome formation.
Despite the protective potential of C3-dependent cell-autonomous immunological mechanisms, an early study showed that the obligate intracellular parasite Leishmania major exploits C3 to enhance its intracellular survival 47 . In contrast to unopsonized parasites, C3-opsonized L. major successfully established parasitism in macrophages attributed to decreased activation of the respiratory burst 47 . Although the opsonizing C3-split products were not specified, it should be noted that leishmanolysin (gp63) cleaves attached C3b into iC3b. Differences in the outcomes of C3-dependent opsonophagocytosis might be attributed to several experimental variables, including the type of organisms, the use of non-immune cells versus professional phagocytes, or the identity of the complement receptors that mediate pathogen entry. When bacterial pathogens enter macrophages via the complement receptor CR3 (e.g., P. gingivalis, Francisella tularensis and Bacillus anthracis spores), they enhance their intracellular persistence and capacity to cause disease in the mouse host 8 (Fig. 2) . The underlying mechanism has been described in detail for F. tularensis, a facultative intracellular bacterium that can escape from the phagosome to replicate within the cytosol. Uptake of F. tularensis is promoted by opsonization via iC3b and engagement of CR3, which activates the kinase Lyn and signaling via the kinase AKT; that, in turn, increases expression of the mitogen-activated protein (MAP) kinase phosphatase MKP-1 and thereby limits MAP-kinase-dependent pro-inflammatory responses downstream of TLR2 (ref. 48) (Fig. 2) . Such outcomes are consistent with the fact that CR3 mediates the efferocytosis of iC3b-coated apoptotic cells, a non-phlogistic process that attenuates cellular activation, including the respiratory burst 1 .
In addition to exploiting specific complement-dependent pathways to their own advantage, pathogens have long been known to r e v i e w block activation of complement in settings in which complement could prevent infection. Mechanistically, pathogens can inhibit complement through mimicry or hijacking of complement-regulatory proteins, proteolytic inactivation of key complement proteins or secretion of complement-inhibitory molecules 9, 49 . The list of evasive pathogens and their specific complement targets has greatly increased in recent years, and apparently inhibition of complement by a pathogen can interfere with both innate immunity and adaptive immunity 9, 50 . Consequently, key virulence factors involved in the evasion of complement are currently considered as vaccine targets for promoting the susceptibility of pathogens to complement-dependent host defenses 9 .
Complement in inflammatory disease
The central role of complement in inflammatory circuits is reflected in its involvement in acute or chronic inflammatory diseases with prominent complement imbalance 3, 51 . As senescence of the innate immune system is increasingly appreciated as a contributor to agingrelated unresolved inflammation 52 , both the magnitude of complement responses and their spatiotemporal regulation can influence aging-related immunodegenerative phenotypes in various tissues. Recent findings have revealed the involvement of complement-driven networks in chronic and aging-related inflammatory conditions ranging from cutaneous, renal and ocular disorders to neuroinflammatory and neurodegenerative disorders 3,33,53-56 .
The central nervous system deploys a distinct set of immunoregulatory and effector pathways, including those mediated by locally produced complement components and resident phagocytes (i.e., microglia) to thwart both infectious inflammatory insults and sterile inflammatory insults 54 . In neurodegenerative conditions, activation of complement engages in cross-talk between neuroinflammatory microglia and reactive astrocytes that fuels tissue-destructive inflammation 57 (Fig. 3a) . Given that synaptic pruning in the developing mammalian brain temporally coincides with complement expression in neuronal and glial progenitors 56, 58 , it has been suggested that postnatal synaptic refinement might be influenced by pathways of the innate immune system that can tag superfluous synaptic material for phagocytic clearance. Seminal studies revealed that C1q promotes synaptic refinement in the postnatal reticulogeniculate system 59 and that clearance of inappropriate synapses is mediated by CR3-expressing microglial cells that engulf C3b-or iC3b-coated synaptic surfaces [59] [60] [61] . This functional link between complement and developmentally regulated synaptic pruning has been recapitulated in animal models of glaucoma, neurodegenerative disease and agingrelated cognitive decline 59, 62, 63 .
Notably, early synapse loss in the adult brain is a common hallmark that precedes cognitive decline in many neurodegenerative disorders 56 . In these settings, a complement-microglial axis has been shown to aberrantly reactivate developmental programs of synaptic pruning and lead to disrupted neuronal connectivity and cognitive Under steady-state conditions, phagocytic cells are constantly eliminated in the subretinal space through a homeostatic mechanism involving the interaction of thrombospondin-1 (TSP-1) with integrin-associated CD47 on subretinal phagocytes. The AMD-associated FH variant H402 potently inhibits the CD47-driven elimination of phagocytes, presumably by binding more effectively to CR3 than the non-risk isoform, and thereby fuels chronic subretinal inflammation. RPE, retinal pigmented epithelium; BM, Bruch's membrane; MΦ, macrophage; IAP, integrin-associated protein.
r e v i e w impairment 56, 64 (Fig. 3a) . A detrimental role for C3 in promoting microglia-dependent synapse elimination has been confirmed in aged C3 −/− mice, which display attenuated synaptic pruning in the hippocampus that results in improved cognitive performance 63 . Furthermore, genetic deficiency in C3 or C3aR mitigates microgliadependent synaptic loss and cognitive impairment in a mouse model of neuroinvasive infection with West Nile virus 65 . Notably, enrichment for C1q and C3 in the cortex of patients with refractory epilepsy is correlated with markers of aberrant microglial activity, which suggests that complement-driven loss of inhibitory synapses might account for the neuronal hyperexcitability observed in human epilepsy 66 .
Alzheimer's disease (AD), the leading cause of age-related dementia worldwide, has as a hallmark robust activation of astrocytes and microglia and deposition of complement on amyloid-β (Aβ) plaques and tangles 67, 68 . While early complement components (C1q and C3) have been associated with the phagocytic clearance of amyloid fibrils, terminal complement effectors (C5a and MAC) have been linked to inflammatory neuronal damage 54 . Consistent with that, therapeutic targeting of C5aR1 ameliorates pathological indexes in various transgenic models of AD 69, 70 . Moreover, neural synaptic loss, an early event in AD pathology that precedes the deposition of amyloid plaques, has been shown to require concerted activation of the classical pathway and CR3-mediated microglial activity 71 . Accordingly, C3 deficiency attenuates synapse loss and cognitive decline in a transgenic model of age-related AD pathology, despite greater accumulation of cerebral Aβ plaques 72 . That last finding indicates an essential role for complement in the phagocytic clearance of Aβ fibrils in the early stages of AD, while C3-dependent pathways seem to exacerbate AD neurodegeneration with age. This dual role for complement in neurodegeneration has wide therapeutic implications.
Augmented Wnt-β-catenin signaling is known to contribute to accelerated aging in mice 73 . C1q has been shown to promote aging-related impairment of muscle regeneration by driving the C1s-dependent cleavage of LRP6, a Wnt co-receptor expressed on myocytes 74 (Fig. 3b) . Notably, C1q-dependent upregulation of Wnt signaling enhances age-related fibrotic changes in the skeletal muscle of mice, which are reversed by genetic ablation of C1q or inhibition of C1s 74 . Since aberrant Wnt signaling is linked to cancer and other degenerative diseases 75 , complement components might promote Wnt-dependent degenerative phenotypes during aging. In support of that possibility, C1q has been shown to promote hypertensioninduced arterial remodeling through enhanced β-catenin signaling and aberrant proliferation of vascular smooth muscle cells 76 . Interestingly, complement downmodulates the expression of Klotho, a transmembrane co-receptor for signaling via fibroblast growth factor that exerts pleiotropic anti-aging functions in various tissues 77 . Consistent with that, early downregulation of Klotho in a porcine model of kidney ischemia-reperfusion was reversed after inhibition of complement by C1 esterase inhibitor 77 .
Age-related macular degeneration (AMD) is a prevalent ocular inflammatory disease and is the chief cause of blindness among the elderly worldwide 53 . Genome-wide association studies have identified polymorphisms in FH as key predisposing factors of AMD 78, 79 . Certain genetic variants are associated with complement dysregulation in the subretinal space and probably contribute to unresolved inflammation, which leads to irreversible loss of photoreceptors 53 . A published study has delineated how the FH variant H402Y might promote inflammatory damage in AMD. The binding of FH to CR3 has been shown to restrain activation of the integrin-associated receptor CD47 by thrombospondin-1, which is required for the homeostatic elimination of subretinal phagocytes 80 (Fig. 3c) . Notably, the AMD-associated FH variant H402Y potentiates this inhibitory effect, which results in pathological subretinal accumulation of phagocytes.
Complement also has an effect on diverse pathologies that involve chronic, low-grade inflammation 3 . A study of mice deficient in C5 and downstream components has linked complement to osteoarthritis, an articular cartilage-degrading disease associated with chronic, low-grade inflammation in synovial joints 81 . Although a connection between complement and another chronic bone-loss disorder, periodontitis, was suggested earlier by correlative clinical studies, subsequent interventional studies of non-human primates have demonstrated a causative link between activation of C3 and inflammatory periodontal bone loss 82, 83 . Furthermore, complement has been linked to Gaucher disease, a genetically driven lysosomal storage disorder associated with dysregulated glycolipid metabolism in various tissues 84 . This disease is associated with chronic inflammation marked by a pronounced autoimmune response to intracellularly accumulated glucosylceramide. Robust clinical evidence and data from animal studies have linked C5a-C5aR1 signaling to a vicious cycle that fuels chronic inflammation in Gaucher disease through C5aR1-driven accumulation of glycolipids and modulation of the generation of glucosylceramide-specific autoantibodies 84 . Finally, the kidneys are particularly susceptible to damage induced by complement-mediated inflammation, which seems to drive various renal disorders 3, 55 .
Collectively, the studies discussed above have identified complement as a key contributor to pathological inflammatory processes, including aging-related diseases. Regarding the latter, an emerging concept is that pathways of the innate immune system that are homeostatically important in early development are aberrantly reactivated in an aging immune system.
Role of complement in cancer
The past decade has identified fundamental molecular pathways that link chronic inflammation to cancer 85, 86 . Beyond genetic and epigenetic modifications that might elicit unrestrained proliferation of cancer cells and their resistance to death, the tumor microenvironment is now acknowledged as acting as a key promoter of tumorigenesis by triggering and supporting local processes of inflammation, angiogenesis and metastasis 87 (Fig. 4) . Given the extensive crosstalk of complement with TLRs, inflammasomes and G-protein-coupled receptors, which determine the activation status of cells of the innate and adaptive immune systems 14, 88, 89 , imbalanced activation of complement in the tumor microenvironment might modulate local immunity and result in inflammation and the suppression of antitumor responses 90 .
Complement has been shown to regulate the differentiation and recruitment of myeloid-derived suppressor cells to tumor sites. Myeloid-derived suppressor cells and dendritic cells, in turn, establish an immunosuppressive environment that restrains anti-tumor T cell responses and thereby allows cancer development 91, 92 . Studies of animal models of melanoma and intestinal, cervical and lung cancer have shown that C3aR-and C5aR1-mediated pathways foster a pro-tumorigenic environment via the activation and polarization of innate immune cells, the release of pro-tumorigenic factors and the suppression of effector T cells 90, [93] [94] [95] [96] [97] [98] . In spontaneous intestinal tumorigenesis in mice with mutation in the gene encoding the tumor suppressor adenomatous polyposis coli, activation of complement was detected locally in the intestine and also systemically after the mice consumed a high-fat diet 94 . In this model, imbalanced complement activation resulted in increased levels of pro-inflammatory cytokines and angiogenic factors, activation of the AKT-NF-κB pathway and the development of intestinal polyps 94 . A published r e v i e w study has provided further support linking complement-induced inflammation to cancer by showing that the long pentraxin PTX3 suppresses mesenchymal and epithelial carcinogenesis by regulating complement-dependent production of chemokines and the recruitment of tumor-promoting macrophages 99 .
Regarding potential mechanisms of complement activation in cancer, studies have demonstrated antibody-independent binding of C1q to phospholipids on the surface of tumor cells and the generation of C5a via direct cleavage of C5 by tumor proteases 100, 101 . Dysregulated activation of complement with increased levels of C3a, C4a or C5a in the circulation has been reported in clinical settings such as hematological and solid-tissue cancers 90 . Furthermore, syngeneic, xenograft and genetic models of tumorigenesis in rodents have indicated that imbalanced activation of complement usually occurs in the tumor stroma, specifically along the vasculature, where activation of complement is associated with angiogenesis and tumor growth 92, 94, 102, 103 .
Complement also promotes the motility and invasiveness of tumor cells through the induction of metalloproteinases from tumor cells, the degradation of extracellular matrix and increased expression of stress fibers and filopodia [104] [105] [106] . C3aR signaling, for example, is linked to the dissemination of cancer to the nervous system via disruption of the blood-cerebrospinal fluid barrier 107 . Additionally, triggering of C3aR-, C5aR1-or MAC-mediated signaling activates PI3K-AKT pathways that culminate in cell proliferation 108, 109 .
Genetic or pharmacological blockade of C3, C3aR or C5aR1 in various cancer models has consistently resulted in inhibition of tumorigenesis 90 . Combined blockade of complement and PD-L1, an immunological checkpoint molecule that downregulates T cell responses, attenuates tumorigenesis in models of melanoma and lung cancer more efficiently than does either therapy individually 100, 110 . Such findings open promising avenues for exploring the inhibition of complement in combination with immunotherapies tailored to reactivate a patient's own anti-cancer immunity.
Complement has also been associated with protective cytotoxic activity for tumor destruction 111 . Moreover, various monoclonal antibodies used in the clinic for the treatment of cancer function to activate complement on the surface of tumor cells and thereby enhance their killing and elimination 112 . Apparently, complement should be tightly regulated to maintain tissue homeostasis. In this context, mice given injection of tumor cells with high expression of C5a (a proinflammatory environment) have fewer effector T cells and more tumorigenesis than do their counterparts given injection of tumors that produce small amounts of C5a (an environment closer to the physiological condition) 113 . Consistent with that, activation of complement along the tumor vasculature modulates endothelial function in a manner that enables efficient recruitment of effector T cells for tumor elimination in a model of cervical cancer 114 .
The studies discussed above indicate that complement has a key role in determining tumor growth by regulating inflammation, T cell immunity and vascularization, as well as the proliferation, migration and invasiveness of tumor cells. However, complement might also stimulate protective anti-tumor responses when it acts in concert with certain cancer therapies.
Molecular basis of complement's functional diversity
Technological advances have enabled new insight into the structure-function relationships of complement components, such as the elucidation of immunoglobulin-triggered activation of complement via the classical pathway. Studies using an elegant liposomal surface model and a combination of structural techniques have demonstrated that after binding to antigen-covered surfaces, immunoglobulin G (IgG) molecules arrange into a hexameric form with a distinct conformational arrangement that facilitates binding and activation of the C1 complex 115 . This model not only provides a molecular explanation for the inability of soluble IgG to activate the classical pathway but also enables the rational design of engineered IgG variants with increased propensity to form hexamers 115, 116 ; these 'hexabodies' might have broad implications for complement-mediated antibody therapy in cancer or infectious or autoimmune diseases 116, 117 .
Other studies have provided molecular insight into the assembly, function and regulation of the alternative-pathway C3 convertase C3bBb 5 . An intricate mechanism driven by conformational changes and tiered interactions enables instant opsonic reactivity while restricting the response to immediate sites of activation 118 (Fig. 5) . For example, both FB and factor D (FD) circulate as mature enzymes but do not mediate cleavage activity in solution. Only after interacting with C3b on target surfaces will FB reveal a hidden binding area for FD. Subsequently, FD docks via an area outside the active site (an 'exosite') and displaces an inhibitory loop to permit cleavage of FB that releases Ba and forms C3bBb 118 . Once the convertase is assembled, C3b is critical for bridging between the C3 substrate and the active site of the convertase to enable activation of C3. Finally, the transient nature of the C3bBb complex and the short-lived surface reactivity of the newly formed C3b largely prevent the opsonization of bystander cells 118 . Emerging molecular knowledge might also elucidate disease implications and therapeutic mechanisms; for example, lampalizumab, a monoclonal antibody to FD that is a therapeutic candidate for the treatment of AMD, binds to the FD exosite and impairs assembly of the convertase 119 , whereas the compstatin family of C3 inhibitors prevents the binding of C3 to the convertase 120 .
Structural characterization of various members of the regulator of complement activation (RCA) family has revealed a common r e v i e w binding mode among FH, CD35, CD46, CD55 and viral homologs, in which subtle differences in domain composition and interaction with C3b determine the functional 'preference' for decay acceleration and cofactor activity 121 . Whereas the former is mediated by steric interference with Bb of the convertase, the cofactor activity of RCA proteins is provided by their ability to form a joint binding site with C3b, which binds factor I (FI) and orients the catalytic site to enable up to three cleavages; this results in degradation into iC3b or C3dg [122] [123] [124] ( Fig. 5) . Notably, analysis of the binding interfaces among C3b, RCA proteins, FB-Bb and/or FI has fostered understanding of why certain polymorphisms or mutations might result in gain-or loss-of-function profiles that contribute to diseases such as AMD, atypical hemolytic uremic syndrome or C3 glomerulopathy. The breakdown of C3b to iC3b and C3dg drives a dynamic process during which the unfolding of domains eliminates binding sites for activators and regulators and concomitantly allows access to receptors such as CR2 and CR3 (refs. 5,123,125) . Molecular analysis of the interaction of the integrin receptors CR3 and CR4 with their C3-derived ligands has revealed differential binding profiles, with only CR3, not CR4, recognizing C3dg as a distinct ligand [126] [127] [128] . In contrast, structural insights into the anaphylatoxin receptors (C3aR, C5aR1 and C5aR2) have remained limited, which is not surprising, given their challenging seven-transmembrane structure. The recent surge of interest in and characterization of other G-protein-coupled receptors has revived the hope that the molecular secrets of the anaphylatoxin receptors will be revealed in the near future. Whereas a detailed picture of the MAC as the second terminal pathway effector has meanwhile been obtained (Fig. 5) , the mechanisms that lead to formation of the C5 convertase and provide selectivity for activating C5 rather than C3 have remained elusive.
Future perspectives
The new mechanisms and functions attributed to complement have transformed the perception of complement from a blood-based innate antimicrobial system to a global regulator of immunity and hostmicrobiome homeostasis. It is now known that complement regulates T cell function not only though paracrine effects (by cytokines released from complement-modulated APCs) but also through T cell-intrinsic effects mediated by complement receptors on or within T cells. A formidable challenge for future research will be to obtain enhanced mechanistic knowledge of how intracellular complement is activated and regulated (or dysregulated) and how such knowledge could be harnessed therapeutically. Moreover, better understanding of the mechanisms that trigger, sustain and amplify complement activation in the tumor microenvironment would facilitate targeted modulation of complement to control carcinogenesis. There are few frontiers remaining in the elucidation of the complement cascade and, given the steady progress on methods and specific inhibitors, it is expected that residual mysteries such as the nature of the C5 convertase can soon be resolved. The true power of emerging structure-function insights, therefore, lies in delineating the crosstalk of complement with other pathways and in the rational development of improved therapeutics. In this context, increased understanding of complement's involvement in chronic and aging-related inflammatory pathologies is expected to shed more light on crosstalk mechanisms and to guide the comprehensive selection of optimal targets of therapeutic intervention in a disease-tailored fashion.
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